Physician profile
Devan Graves
NPI 1811666761
$12,249.60
in general payments reported to CMS, 2019-2025
24 companies · $2,665 in 2025
The $2,665 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $3,322 · 2023: $3,265 · 2024: $2,789 · 2025: $2,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,719.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,197.67 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,336.88 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,177.95 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Vanda Pharmaceuticals INC. | $1,048.76 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $951.75 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $880.96 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $829.96 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $728.33 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $647.59 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $415.40 | 2022-2025 | Rexulti |
| Noven Therapeutics, LLC | $375.40 | 2023-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $306.92 | 2022-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $198.00 | 2022-2024 | Loreev Xr, Gralise |
| Axsome Therapeutics, INC. | $190.28 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $181.87 | 2024 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $161.41 | 2022-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $144.01 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $115.12 | 2022-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $109.52 | 2024 | |
| Neos Therapeutics, Lp | $108.75 | 2023-2025 | Adzenys Xr-Odt |
| Tris Pharma INC | $79.07 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $23.87 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $20.51 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devan Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.